CNS Protein Therapeutics raising angel round for Parkinson’s research
A recently started company in Palo Alto, Calif. called CNS Protein Therapeutics is seeking a round of $1-2 million for research into Parkinson’s and other neurodegenerative diseases, according to a regulatory filing obtained by VentureBeat.
The company appears to have taken about a quarter of a planned $1 million funding from its founders, John and Gerald Commissiong. However, a profile on GoBig Network indicates that the company may be looking for $2 million.
John Commissiong has a Ph.D., with a background in neurophysiology and molecular neuroscience, according to summary here. He is also listed as president and CEO of a company called Neurotrohics in Toronto, Canada.
Next Story: The battle to fund Twitter
Previous Story: Microsoft Live Search: If at first you don’t succeed, pay your users
About the Author, Chris Morrison
Chris Morrison writes about cleantech and environmental issues for VentureBeat, with occasional forays into gaming and semantic technology. He got his start writing about tech for Business 2.0 magazine, but quickly realized new media was the ticket when that institution closed its doors in 2007. Chris has also covered public equities and regulatory issues. He originally hails from southern Virginia, graduated from Evergreen State College in Washington, and now lives in San Francisco.